Lars Fruergaard Jorgensen, Novo Nordisk CEO (Photographer: Chris Ratcliffe/Bloomberg via Getty Images)

No­vo Nordisk to spend $747M+ on ex­pan­sions and new fa­cil­i­ty in Den­mark

The Dan­ish phar­ma gi­ant No­vo Nordisk is mak­ing a ma­jor ex­pan­sion close to home.

The com­pa­ny an­nounced on Tues­day that it plans to in­vest 5.4 bil­lion Dan­ish kro­ner ($747.2 mil­lion) in­to ex­pand­ing its ex­ist­ing fa­cil­i­ties in its home­town of Bagsværd, Den­mark, a sub­urb of Copen­hagen. Those plans al­so in­clude the con­struc­tion of a new plant.

A No­vo Nordisk spokesper­son did not con­firm the size of the new plant to End­points News by press time. How­ev­er, they did tell End­points that de­spite the ex­pan­sion of ex­ist­ing fa­cil­i­ties, the man­u­fac­tur­ing of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (API) is cur­rent­ly on­go­ing to sup­port clin­i­cal tri­als. The ex­pan­sions are ex­pect­ed to be fi­nal­ized and ful­ly op­er­a­tional in Au­gust of next year for pu­rifi­ca­tion. The new fa­cil­i­ty, which is cen­tered around fer­men­ta­tion and re­cov­ery, is ex­pect­ed to be fi­nal­ized in Au­gust 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.